Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 14;16(3):341.
doi: 10.3390/genes16030341.

MYOSLID: A Critical Modulator of Cancer Hallmarks

Kanupriya Medhi  1 , Sagarika Mukherjee  1 , Aastha Dagar  1 , Ashutosh Kumar Tiwari  1 , Sia Daffara  1 , Sanjana Bana  1 , Vivek Uttam  1 , Md Rizwan Ansari  2 , Vikas Yadav  3 , Hardeep Singh Tuli  4 , Aklank Jain  1
Affiliations
Review

MYOSLID: A Critical Modulator of Cancer Hallmarks

Kanupriya Medhi et al. Genes (Basel). .

Abstract

Despite being the leading cause of death worldwide, cancer still lacks precise biomarkers for effective targeting, limiting efforts to reduce mortality rates. This review explores the role and clinical significance of a newly identified long non-coding RNA, MYOSLID, in cancer progression. MYOSLID has emerged as a critical modulator in cancer progression by influencing key hallmarks such as proliferation, immune evasion, metastasis, and metabolic reprogramming. It promotes tumor cell growth by stabilizing hypoxia-inducible factor 1 and acting as a competing endogenous RNA (ceRNA) to sequester tumor-suppressive microRNAs like miR-29c-3p, thereby enhancing oncogene expression. It facilitates immune evasion by upregulating PD-L1, suppressing T cell activation, and modulating necroptosis pathways involving RIPK1 and RIPK3. Additionally, MYOSLID drives metastasis by regulating epithelial-mesenchymal transition markers such as LAMB3 and Slug while promoting RAB13-mediated cytoskeletal remodeling and enhancing cancer cell invasion. We have obtained the expression of MYOSLID from TCGA and the ENCORI database. The expression of colorectal adenocarcinoma (COAD) and head and neck squamous cell carcinoma (HNSCC) is associated with poor prognosis and lower survival rate. Given its significant potential as a diagnostic biomarker and therapeutic target, further research is required to elucidate its precise molecular mechanisms and therapeutic applications in cancer treatment.

Keywords: LncRNA; MYOSLID; activating invasion and metastasis; avoiding immune destruction and cell death resistance; cancer hallmarks; colorectal cancer; deregulating cellular metabolism; gastric cancer; head and neck squamous cell carcinoma; oral cell squamous carcinoma; osteosarcoma; sustaining proliferative signaling.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest to report.

Figures

Figure 1
Figure 1
Role of MYOSLID in various cancers (Created with BioRender.com).
Figure 2
Figure 2
Upregulatory effect of MYOSLID in modulation of various cancer hallmarks. [Note: ↑—upregulation, ↓—downregulation] (Created with BioRender.com).
Figure 3
Figure 3
Data plots of Kaplan–Meier estimate overall survival of a group of patients retrieved from TCGA database (https://ualcan.path.uab.edu/, accessed on 4 December 2024): (A) head and neck squamous cell carcinoma; (B) colon adenocarcinoma (COAD).
Figure 4
Figure 4
Differential expression of LncRNA MYOSLID in various cancer in the ENCORI database on 4 December 2024. (A) Colon adenocarcinoma (COAD). (B) Head and neck squamous cell carcinoma (HNSC). (C) Stomach Adenocarcinoma (STAD).
Figure 5
Figure 5
DAVID functional enrichment analysis of MYOSLID target genes in various biological processes and signaling pathways. (A) Significantly enriched GO biological terms. (B) Significantly enriched GO processes. (C) Significantly enriched KEGG pathway.
See this image and copyright information in PMC

References

    1. Sammarco G., Gallo G., Vescio G., Picciariello A., De Paola G., Trompetto M., Curro G., Ammendola M. Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. J. Clin. Med. 2020;9:2852. doi: 10.3390/jcm9092852. - DOI - PMC - PubMed
    1. Zhong X., He X., Wang Y., Hu Z., Yu D., Huang H., Zhao S., Wei P., Li D. A Hypoxia-Related lncRNA Signature Correlates with Survival and Tumor Microenvironment in Colorectal Cancer. J. Immunol. Res. 2022;2022:9935705. doi: 10.1155/2022/9935705. - DOI - PMC - PubMed
    1. Sharma U., Barwal T.S., Khandelwal A., Malhotra A., Rana M.K., Singh Rana A.P., Imyanitov E.N., Vasquez K.M., Jain A. LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3. Biochimie. 2021;182:99–107. doi: 10.1016/j.biochi.2020.12.026. - DOI - PubMed
    1. Sharma U., Kaur Rana M., Singh K., Jain A. LINC00324 promotes cell proliferation and metastasis of esophageal squamous cell carcinoma through sponging miR-493-5p via MAPK signaling pathway. Biochem. Pharmacol. 2023;207:115372. doi: 10.1016/j.bcp.2022.115372. - DOI - PubMed
    1. Sharma U., Barwal T.S., Murmu M., Acharya V., Pant N., Dey D., Vivek, Gautam A., Bazala S., Singh I., et al. Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers. Biomark. Med. 2022;16:349–369. doi: 10.2217/bmm-2021-0682. - DOI - PubMed